High expression of ATP5A1 in gastric carcinoma is correlated with a poor prognosis and enhanced glucose metabolism in tumor cells

doi:10.12122/j.issn.1673-4254.2024.05.20

Abstract

Abstract:

Objective To analyze the expression level of ATP5A1 in gastric carcinoma and its influence on the prognosis of the patients and glucose metabolism in the tumor cells. Methods We retrospectively analyzed the data of 115 patients undergoing radical resection of gastric carcinoma in our hospital from February, 2013 to November, 2016. ATP5A1 expression in the surgical specimens were detected using immunohistochemistry, and the long-term prognosis of the patients with high (n=58) and low ATP5A1 expression (n=57) were analyzed. In gastric carcinoma MGC803 cells, the effects of lentivirus-mediated ATP5A1 knockdown or overexpression on glucose metabolism were investigated. We also observed the growth and glucose metabolism of xenografts derived from MGC803 cells with ATP5A1 knockdown or overexpression in nude mice. Results ATP5A1 was significantly overexpressed in gastric carcinoma tissues in close correlation with blood CEA and CA19-9 levels, pathological grade, T stage and N stage (P<0.05). ATP5A1 overexpression was an independent risk factor for a significantly lowered 5-year survival rate of patients with gastric carcinoma (P<0.05). ROC curve analysis demonstrated the predictive value of high ATP5A1 expression for the patients' prognosis (P<0.001). In MGC803 cells, ATP5A1 overexpression significantly up-regulated cellular glucose uptake and lactate production and increased the protein levels of HK2, PFK1, and LDHA (P<0.05), while ATP5A1 knockdown produced the opposite changes (P<0.05). In the tumor-bearing mice, overexpression of ATP5A1 increased glucose metabolism of the tumor cells and promoted tumor growth (P<0.05). Overexpression of ATP5A1 promoted the expressions of p-JNK and p-JUN in MGC803 cells (P<0.05), and the JNK inhibitor SP600125 significantly inhibited the enhancement of cellular glucose metabolism induced by ATP5A1 overexpression (P<0.05). Conclusion High ATP5A1 expression in gastric cancer is associated a poor long-term prognosis of the patients, and its effect is mediated at least partly by promoting glucose metabolism of the cells through the JNK/JUN pathway.

Key words: ATP5A1, gastric carcinoma, glucose metabolism, prognosis, JNK/JUN pathway

Jingjing YANG, Lixia YIN, Ting DUAN, Minzhu NIU, Zhendong HE, Xinrui CHEN, Xiaofeng ZHANG, Jing LI, Zhijun GENG, Lugen ZUO. High expression of ATP5A1 in gastric carcinoma is correlated with a poor prognosis and enhanced glucose metabolism in tumor cells[J]. Journal of Southern Medical University, 2024, 44(5): 974-980.

Figures/Tables 8

Fig.1 ATP5A1 is overexpressed in gastric carcinoma tissues. A: Immunohistochemistry of ATP5A1 in gastric carcinoma and adjacent tissues. B: IOD values of ATP5A1 expression in gastric carcinoma and adjacent tissues. *P<0.05 vs adjacent tissue.

Tab.1 Clinical data of 115 patients with gastric carcinoma

Factors		n	ATP5A1 expression (n, %)		χ²	P
Factors		n	Low (n=57)	High (n=58)	χ²	P
Gender	Male	85	42 (49.41%)	43 (50.59%)	0.003	0.956
Gender	Female	30	15 (50.00%)	15 (50.00%)	0.003	0.956
Age (year)	<60	40	20 (50.00%)	20 (50.00%)	0.005	0.946
Age (year)	≥60	75	37 (49.33%)	38 (50.67%)	0.005	0.946
CEA (μg/L)	<5	54	35 (64.81%)	19 (35.19%)	9.470	0.002
CEA (μg/L)	≥5	61	22 (36.07%)	39 (63.93%)	9.470	0.002
CA19-9 (kU/L)	<37	55	38 (69.09%)	17 (30.91%)	16.077	<0.001
CA19-9 (kU/L)	≥37	60	19 (31.67%)	41 (68.33%)	16.077	<0.001
Tumor size (cm)	<5	53	30 (56.60%)	23 (43.40%)	1.948	0.163
Tumor size (cm)	≥5	62	27 (43.55%)	35 (56.45%)	1.948	0.163
Pathological grading	G1-2	60	36 (60.00%)	24 (40.00%)	5.464	0.019
Pathological grading	G3-4	55	21 (38.18%)	34 (61.82%)	5.464	0.019
Cancer cell type	Adenocarcinoma	90	47 (52.22%)	43 (47.78%)	1.169	0.280
Cancer cell type	Other	25	10 (40.00%)	15 (60.00%)	1.169	0.280
T stage	T1-T2	60	38 (63.33%)	22 (36.67%)	9.513	0.002
T stage	T3-T4	55	19 (34.55%)	36 (65.45%)	9.513	0.002
N stage	N0-N1	66	43 (65.15%)	23 (34.85%)	15.053	<0.001
N stage	N2-N3	49	14 (28.57%)	35 (71.43%)	15.053	<0.001

Fig.2 Relationship between ATP5A1 expression and prognosis in patients with gastric carcinoma.

Tab.2 Factors affecting postoperative survival of patients with gastric carcinoma

Factors	Univariate analysis		Multivariate analysis
Factors	Log-rank χ ²	P	HR	95% CI	P
Gender (female vs male)	1.436	0.231
Age (≥60 year vs <60 year)	0.745	0.388
ATP5A1 expression (high vs low)	30.968	<0.001	2.771	1.458-5.267	0.002
CEA (≥5 μg/L vs <5 μg/L)	16.152	<0.001	2.003	1.097-3.658	0.024
CA19-9 (≥37 kU/L vs <37kU/L)	35.142	<0.001	3.348	1.666-6.728	0.001
Tumor size (≥5 cm vs <5 cm)	0.077	0.782
Pathological grading (G3-G4 vs G1-G2)	32.142	<0.001	2.759	1.484-5.128	0.001
Cancer cell type (adenocarcinoma vs other)	1.251	0.263
T stage (T3-T4 vs T1-T2)	27.798	<0.001	2.056	1.122-3.768	0.020
N stage (N2-N3 vs N0-N1)	28.006	<0.001	2.251	1.211-4.187	0.010

Fig.3 Sensitivity and specificity of ATP5A1 expression for predicting postoperative survival of patients with gastric carcinoma.

Fig.4 Overexpression of ATP5A1 accelerates glucose metabolism in gastric carcinoma cells. A, B: Western blotting for detecting ATP5A1 protein after lentivirus transfection. C, D: Glucose uptake and lactate production of the gastric cancer cells. E, F: Western blotting for the proteins related to glucose metabolism. *P<0.05 vs Control.

Fig.5 ATP5A1 promotes glucose metabolism by activating the JNK/JUN signaling pathway. A, B: Phosphorylation levels of JNK and JUN detected by Western blotting. C, D: Glucose uptake and lactate production in gastric cancer cells. E, F: Western blotting for detecting glucose metabolism-related protein expressions. *P<0.05 vs Control. #P<0.05 vs LV-ATP5A1.

Fig.6 Overexpression of ATP5A1 accelerates tumor growth and glucose metabolism in nude mice. A: Tumor xenografts in the 3 groups. B: Weight of the transplanted tumors. C: Volume of the transplanted tumors. D, E: Protein expressions of HK2, PFK1 and LDHA in xenografts detected by Western blotting. *P<0.05 vs Control.

References 30

1	Smyth EC, Nilsson M, Grabsch HI, et al. Gastric cancer[J]. Lancet, 2020, 396(10251): 635-48. DOI: 10.1016/s0140-6736(20)31288-5
2	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-49. DOI: 10.3322/caac.21660
3	Xia CF, Dong XS, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J, 2022, 135(5): 584-90. DOI: 10.1097/cm9.0000000000002108
4	Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods[J]. Int J Cancer, 2019, 144(8): 1941-53. DOI: 10.1002/ijc.31937
5	Zhang KC, Chen L. Chinese consensus on the diagnosis and treatment of gastric cancer with liver metastases[J]. Ther Adv Med Oncol, 2020, 12: 1758835920904803. DOI: 10.1177/1758835920904803
6	Tan ZY. Recent advances in the surgical treatment of advanced gastric cancer: a review[J]. Med Sci Monit, 2019, 25: 3537-41. DOI: 10.12659/msm.916475
7	Yang YQ, Ma YF, Xiang XY, et al. The prognostic value of the lymph node ratio for local advanced gastric cancer patients with intensity-modulated radiation therapy and concurrent chemotherapy after radical gastrectomy in China[J]. Radiat Oncol, 2020, 15(1): 237. DOI: 10.1186/s13014-020-01687-0
8	Nakayama I, Takahari D. The role of angiogenesis targeted therapies in metastatic advanced gastric cancer: a narrative review[J]. J Clin Med, 2023, 12(9): 3226. DOI: 10.3390/jcm12093226
9	Lin JX, Lian NZ, Gao YX, et al. m6A methylation mediates LHPP acetylation as a tumour aerobic glycolysis suppressor to improve the prognosis of gastric cancer[J]. Cell Death Dis, 2022, 13(5): 463. DOI: 10.1038/s41419-022-04859-w
10	Zhao HY, Jiang RK, Feng ZJ, et al. Transcription factor LHX9 (LIM Homeobox 9) enhances pyruvate kinase PKM2 activity to induce glycolytic metabolic reprogramming in cancer stem cells, promoting gastric cancer progression[J]. J Transl Med, 2023, 21(1): 833. DOI: 10.1186/s12967-023-04658-7
11	Pouysségur J, Marchiq I, Parks SK, et al. ‘Warburg effect' controls tumor growth, bacterial, viral infections and immunity-Genetic deconstruction and therapeutic perspectives[J]. Semin Cancer Biol, 2022, 86(Pt 2): 334-46. DOI: 10.1016/j.semcancer.2022.07.004
12	Jonckheere AI, Smeitink JAM, Rodenburg RJT. Mitochondrial ATP synthase: architecture, function and pathology[J]. J Inherit Metab Dis, 2012, 35(2): 211-25. DOI: 10.1007/s10545-011-9382-9
13	Jana S, Heaven MR, Stauft CB, et al. HIF-1α-dependent metabolic reprogramming, oxidative stress, and bioenergetic dysfunction in SARS-CoV-2-infected hamsters[J]. Int J Mol Sci, 2022, 24(1): 558. DOI: 10.3390/ijms24010558
14	Li JB, Wang JZ, Pan TH, et al. USP25 deficiency promotes T cell dysfunction and transplant acceptance via mitochondrial dynamics[J]. Int Immunopharmacol, 2023, 117: 109917. DOI: 10.1016/j.intimp.2023.109917
15	梁亚敏. TET2/ATP5A1在低剪切应力诱导内皮间质转化中的作用及机制研究[D]. 衡阳: 南华大学, 2022.
16	Ba YS, Ma FW, Ma YW, et al. ATP5A1 participates in transcriptional and posttranscriptional regulation of cancer-associated genes by modulating their expression and alternative splicing profiles in HeLa cells[J]. Technol Cancer Res Treat, 2021, 20: 15330338211039126. DOI: 10.1177/15330338211039126
17	Pan J, Sun LC, Tao YF, et al. ATP synthase ecto-α-subunit: a novel therapeutic target for breast cancer[J]. J Transl Med, 2011, 9: 211. DOI: 10.1186/1479-5876-9-211
18	杨素丽. ATP5A1在大肠癌中的表达及其临床意义[D]. 长春: 吉林大学, 2017.
19	Li M, Wang M, Xi Y, et al. Isolation and identification of a Tibetan pig porcine epidemic diarrhoea virus strain and its biological effects on IPEC-J2 cells[J]. Int J Mol Sci, 2024, 25(4): 2200. DOI: 10.3390/ijms25042200
20	Choi Y, Park J, Choi Y, et al. C-Jun N-terminal kinase activation has a prognostic implication and is negatively associated with FOXO1 activation in gastric cancer[J]. BMC Gastroenterol, 2016, 16(1): 59. DOI: 10.1186/s12876-016-0473-9
21	Zhang L, Gao YG. ICOSLG acts as an oncogene to promote glycolysis, proliferation, migration, and invasion in gastric cancer cells[J]. Arch Biochem Biophys, 2024, 752: 109841. DOI: 10.1016/j.abb.2023.109841
22	Peng CZ, Yang X, Li X, et al. ALDOB plays a tumor-suppressive role by inhibiting AKT activation in gastric cancer[J]. J Cancer, 2023, 14(12): 2255-62. DOI: 10.7150/jca.83456
23	Xu GY, Li JY. ATP5A1 and ATP5B are highly expressed in glioblastoma tumor cells and endothelial cells of microvascular proliferation[J]. J Neurooncol, 2016, 126(3): 405-13. DOI: 10.1007/s11060-015-1984-x
24	Yuan LS, Chen L, Qian KY, et al. A novel correlation between ATP5A1 gene expression and progression of human clear cell renal cell carcinoma identified by co-expression analysis[J]. Oncol Rep, 2018, 39(2): 525-36.
25	Martínez-Esquivias F, Gutiérrez-Angulo M, Becerra-Ruiz JS, et al. Bioinformatic analysis of the effect of silver nanoparticles on colorectal cancer cell line[J]. Biomed Res Int, 2022, 2022: 6828837. DOI: 10.1155/2022/6828837
26	Zhang GF, Zhong JM, Lin L, et al. Loss of ATP5A1 enhances proliferation and predicts poor prognosis of colon adenocarcinoma[J]. Pathol Res Pract, 2022, 230: 153679. DOI: 10.1016/j.prp.2021.153679
27	Bose S, Zhang C, Le A. Glucose metabolism in cancer: the Warburg effect and beyond[J]. Adv Exp Med Biol, 2021, 1311: 3-15. DOI: 10.1007/978-3-030-65768-0_1
28	Liberti MV, Locasale JW. The Warburg effect: how does it benefit cancer cells?[J]. Trends Biochem Sci, 2016, 41(3): 211-8. DOI: 10.1016/j.tibs.2015.12.001
29	Yang HL, Lin PY, Vadivalagan C, et al. Coenzyme Q0 defeats NLRP3-mediated inflammation, EMT/metastasis, and Warburg effects by inhibiting HIF-1α expression in human triple-negative breast cancer cells[J]. Arch Toxicol, 2023, 97(4): 1047-68. DOI: 10.1007/s00204-023-03456-w
30	Mi YS, Li QH, Liu BT, et al. Ubiquitous mitochondrial creatine kinase promotes the progression of gastric cancer through a JNK-MAPK/JUN/HK2 axis regulated glycolysis[J]. Gastric Cancer, 2023, 26(1): 69-81. DOI: 10.1007/s10120-022-01340-7

[1]	Jinlong PANG, Xinli ZHAO, Zhen ZHANG, Haojie WANG, Xingqi ZHOU, Yumei YANG, Shanshan LI, Xiaoqiang CHANG, Feng LI, Xian LI. Overexpression of multimerin-2 promotes cutaneous melanoma cell invasion and migration and is associated with poor prognosis [J]. Journal of Southern Medical University, 2025, 45(7): 1479-1489.
[2]	Xuan WU, Jiamin FANG, Weiwei HAN, Lin CHEN, Jing SUN, Qili JIN. High PRELID1 expression promotes epithelial-mesenchymal transition in gastric cancer cells and is associated with poor prognosis [J]. Journal of Southern Medical University, 2025, 45(7): 1535-1542.
[3]	Kang WANG, Haibin LI, Jing YU, Yuan MENG, Hongli ZHANG. High expression of ELFN1 is a prognostic biomarker and promotes proliferation and metastasis of colorectal cancer cells [J]. Journal of Southern Medical University, 2025, 45(7): 1543-1553.
[4]	Yi ZHANG, Yu SHEN, Zhiqiang WAN, Song TAO, Yakui LIU, Shuanhu WANG. High expression of CDKN3 promotes migration and invasion of gastric cancer cells by regulating the p53/NF-κB signaling pathway and inhibiting cell apoptosis [J]. Journal of Southern Medical University, 2025, 45(4): 853-861.
[5]	Qingqing HUANG, Wenjing ZHANG, Xiaofeng ZHANG, Lian WANG, Xue SONG, Zhijun GENG, Lugen ZUO, Yueyue WANG, Jing LI, Jianguo HU. High MYO1B expression promotes proliferation, migration and invasion of gastric cancer cells and is associated with poor patient prognosis [J]. Journal of Southern Medical University, 2025, 45(3): 622-631.
[6]	Huali LI, Ting SONG, Jiawen LIU, Yongbao LI, Zhaojing JIANG, Wen DOU, Linghong ZHOU. Prognosis-guided optimization of intensity-modulated radiation therapy plans for lung cancer [J]. Journal of Southern Medical University, 2025, 45(3): 643-649.
[7]	Xue SONG, Yue CHEN, Min ZHANG, Nuo ZHANG, Lugen ZUO, Jing LI, Zhijun GENG, Xiaofeng ZHANG, Yueyue WANG, Lian WANG, Jianguo HU. GPSM2 is highly expressed in gastric cancer to affect patient prognosis by promoting tumor cell proliferation [J]. Journal of Southern Medical University, 2025, 45(2): 229-238.
[8]	Tianwei TANG, Luan LI, Yuanhan CHEN, Li ZHANG, Lixia XU, Zhilian LI, Zhonglin FENG, Huilin ZHANG, Ruifang HUA, Zhiming YE, Xinling LIANG, Ruizhao LI. High serum cystatin C is an independent risk factor for poor renal prognosis in IgA nephropathy [J]. Journal of Southern Medical University, 2025, 45(2): 379-386.
[9]	Xiaorui CHEN, Qingzheng WEI, Zongliang ZHANG, Jiangshui YUAN, Weiqing SONG. Overexpression of CHMP2B suppresses proliferation of renal clear cell carcinoma cells [J]. Journal of Southern Medical University, 2025, 45(1): 126-136.
[10]	Yaobin WANG, Liuyan CHEN, Yiling LUO, Jiqing SHEN, Sufang ZHOU. Predictive value of NUF2 for prognosis and immunotherapy responses in pan-cancer [J]. Journal of Southern Medical University, 2025, 45(1): 137-149.
[11]	Chao ZHOU, Jingjing ZHANG, Qiao TANG, Shuangnan FU, Ning ZHANG, Zhaoyun HE, Jin ZHANG, Tianyi ZHANG, Pengcheng LIU, Man GONG. Value of serum tryptophan in stratified management of 90-day mortality risk in patients with hepatitis B virus-related acute-on-chronic liver failure: a multicenter retrospective study [J]. Journal of Southern Medical University, 2025, 45(1): 59-64.
[12]	Xiaohua CHEN, Hui LU, Ziliang WANG, Lian WANG, Yongsheng XIA, Zhijun GENG, Xiaofeng ZHANG, Xue SONG, Yueyue WANG, Jing LI, Jianguo HU, Lugen ZUO. Role of Abelson interactor 2 in progression and prognosis of gastric cancer and its regulatory mechanisms [J]. Journal of Southern Medical University, 2024, 44(9): 1653-1661.
[13]	Mengnan YE, Hongmei WU, Yan MEI, Qingling ZHANG. High expression of CREM is associated with poor prognosis in gastric cancer patients [J]. Journal of Southern Medical University, 2024, 44(9): 1776-1782.
[14]	Kai JI, Guanyu YU, Leqi ZHOU, Tianshuai ZHANG, Qianlong LING, Wenjiang MAN, Bing ZHU, Wei ZHANG. HNRNPA1 gene is highly expressed in colorectal cancer: its prognostic implications and potential as a therapeutic target [J]. Journal of Southern Medical University, 2024, 44(9): 1685-1695.
[15]	Yan WANG, Yuqing RUAN, Can CUI, Xiu WANG. Jiaotaiwan improves brain glucose metabolism in a mouse model of Alzheimer's disease by activating the PI3K/AKT signaling pathway [J]. Journal of Southern Medical University, 2024, 44(5): 894-903.